Related Experiment Videos
Serine derived NK1 antagonists. 2: A pharmacophore model for arylsulfonamide binding
J M Elliott1, H Broughton, M A Cascieri
1Merck Sharp and Dohme Research Laboratories, Neuroscience Research Center, Harlow, Essex, U.K.
Bioorganic & Medicinal Chemistry Letters
|January 5, 1999
Summary
Researchers modified serine-derived neurokinin-1 (NK1) antagonists. These modifications to the spirocyclic aryl sulfonamide part enabled the creation of a partial pharmacophore model.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Neurokinin-1 (NK1) receptor antagonists are investigated for therapeutic applications.
- The spirocyclic aryl sulfonamide moiety is a key structural feature in certain NK1 antagonists.
Purpose of the Study:
- To explore the impact of modifications to the spirocyclic aryl sulfonamide portion of serine-derived NK1 antagonists.
- To develop a partial pharmacophore model based on these structural alterations.
Main Methods:
- Systematic chemical modifications of the spirocyclic aryl sulfonamide group in serine-derived NK1 antagonists.
- Pharmacological evaluation of modified compounds.
- Development of a pharmacophore model integrating structural and activity data.
Main Results:
- Specific modifications to the spirocyclic aryl sulfonamide significantly influenced NK1 antagonist activity.
- A partial pharmacophore model was successfully developed, outlining key interactions for NK1 receptor binding.
- Structure-activity relationships were elucidated for the modified series.
Conclusions:
- Modifications of the spirocyclic aryl sulfonamide are a viable strategy for tuning NK1 antagonist properties.
- The developed pharmacophore model provides insights into the rational design of novel NK1 receptor ligands.